Format

Send to

Choose Destination
See comment in PubMed Commons below
Vaccine. 2014 Mar 5;32(11):1296-303. doi: 10.1016/j.vaccine.2013.12.057. Epub 2014 Jan 4.

Cross-species protection: Schistosoma mansoni Sm-p80 vaccine confers protection against Schistosoma haematobium in hamsters and baboons.

Author information

  • 1Center for Tropical Medicine and Infectious Diseases, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA; Department of Immunology and Molecular Microbiology, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA.
  • 2Department of Natural Sciences, School of Arts & Sciences, Peru State College, Peru, NE 68321, USA.
  • 3Tulane National Primate Research Center, Covington, LA 70433, USA.
  • 4Department of Cellular Biology, University of Georgia, Athens, GA 30602, USA.
  • 5Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
  • 6Infectious Disease Research Institute, Seattle, WA 98102, USA; PAI Life Sciences, Seattle, WA 98102, USA.
  • 7Infectious Disease Research Institute, Seattle, WA 98102, USA.
  • 8Center for Tropical Medicine and Infectious Diseases, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA; Department of Immunology and Molecular Microbiology, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA; Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA; Department of Pathology, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA. Electronic address: Afzal.Siddiqui@ttuhsc.edu.

Abstract

The ability of the Schistosoma mansoni antigen, Sm-p80, to provide cross-species protection against Schistosoma haematobium challenge was evaluated in hamster and baboon models. Pronounced reduction in worm burden (48%) and in tissue egg load (64%) was observed in hamsters vaccinated with recombinant Sm-p80 admixed with glucopyranosyl lipid adjuvant-stable emulsion (GLA-SE). Similarly, in baboons, the Sm-p80/GLA-SE vaccine produced a 25% reduction in S. haematobium adult worms and decreased the egg load in the urinary bladder by 64%. A 40% and 53% reduction in fecal and urine egg output, respectively, was observed in vaccinated baboons. A balanced pro-inflammatory (Th17 and Th1) and Th2 type of response was generated after vaccination and appears indicative of augmented prophylactic efficacy. These data on cross-species protection coupled with the prophylactic, therapeutic and antifecundity efficacy against the homologous parasite, S. mansoni, reinforces Sm-p80 as a promising vaccine candidate. It is currently being prepared for GMP-compliant manufacture and for further pre-clinical development leading to human clinical trials. These results solidify the expectation that the Sm-p80 vaccine will provide relief for both the intestinal and the urinary schistosomiasis and thus will be greatly beneficial in reducing the overall burden of schistosomiasis.

Copyright © 2013 Elsevier Ltd. All rights reserved.

KEYWORDS:

Baboons; Calpain; Intestinal schistosomiasis; Nonhuman primate; Schistosoma haematobium; Schistosoma mansoni; Schistosome vaccine; Sm-p80; Urinary schistosomiasis

[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk